
-
Regenxbio NasdaqGS:RGNX REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Location: 9804 Medical Center Drive, Rockville, MD, 20850, United States | Website: https://www.regenxbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
315.6M
Cash
267.9M
Avg Qtr Burn
-21.01M
Short % of Float
15.33%
Insider Ownership
7.59%
Institutional Own.
88.18%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Clemidsogene lanparvovec (RGX-121) Details Mucopolysaccharidosis II (MPS II), aka Hunter syndrome | PDUFA Approval decision | |
ABBV-RGX-314 (Suprachoroidal Delivery) Details Diabetes, Eye disease , Diabetic retinopathy | Phase 3 Initiation | |
RGX-202 Details Rare diseases, Genetic disorder, Rare genetic disease, Duchenne muscular dystrophy | Phase 2/3 Update | |
ABBV-RGX-314 (Suprachoroidal Delivery) Details Eye disease , Age-related macular degeneration, Wet age-related macular degeneration | Phase 2 Data readout | |
ABBV-RGX-314 (Subretinal Delivery) Details Eye disease , Wet age-related macular degeneration , Age-related macular degeneration | Phase 2 Data readout | |
RGX-381 Details Central nervous system illness | Phase 1/2 Data readout | |
RGX-111 Details Mucopolysaccharidoses, Rare genetic disease, Genetic disorder, Rare diseases, Mucopolysaccharidosis Type 1 | Phase 1/2 Update | |
RGX-181 Details Central nervous system illness, Batten Disease | Phase 1 Data readout |